Late Cornified Envelope Protein 3E: Potential Drug Target Or Biomarker

Target Name: LCE3E

NCBI ID: G353145

LCE3E

Late Cornified Envelope Protein 3E: Potential Drug Target Or Biomarker

Late cornified envelope protein 3E (LCE3E) is a protein that is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. It is a member of the late cornified envelope (LE) family of proteins, which are involved in various cellular processes, including cell signaling and tissue structure.

Recent studies have suggested that LCE3E may have important roles in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This has led to renewed interest in LCE3E as a potential drug target or biomarker.

One of the key functions of LCE3E is its role in cell signaling. LCE3E is a potent negative regulator of the PI3K/Akt signaling pathway, which is involved in various cellular processes, including cell survival, proliferation, and angiogenesis. This means that when LCE3E is activated, it can inhibit the activity of the PI3K/Akt signaling pathway, leading to cellular responses that are opposite to those that would be observed with inhibition of the pathway.

This ability of LCE3E to regulate cell signaling has important implications for its potential as a drug target. By targeting LCE3E with small molecules or other compounds, researchers may be able to disrupt its negative regulation of the PI3K/Akt signaling pathway and trigger various cellular responses that can be useful for therapeutic applications. For example, LCE3E has been shown to play a role in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. By targeting LCE3E with drugs that can disrupt its negative regulation of the PI3K/Akt signaling pathway, researchers may be able to develop new treatments for these debilitating conditions.

Another potential application of LCE3E is its role as a biomarker for certain diseases. LCE3E is expressed in a variety of tissues throughout the body, including the brain, pancreas, and gastrointestinal tract. This makes it a potential target for biomarkers that can be used to diagnose or monitor the progression of diseases. For example, LCE3E has been shown to be expressed in the brains of individuals with Alzheimer's disease, and may be a useful biomarker for this disease. Similarly, LCE3E has been shown to be expressed in the pancreatic tissue of individuals with insulin-dependent diabetes mellitus, and may be a useful biomarker for this disease.

In addition to its potential as a drug target or biomarker, LCE3E is also of interest as a potential therapeutic agent. LCE3E has been shown to play a role in various cellular processes that are important for cellular survival and growth, and may be a useful agent for promoting cellular regression or apoptosis in cancer cells. Additionally, LCE3E may be a useful agent for promoting cellular survival and growth in neurodegenerative diseases, such as Alzheimer's disease.

In conclusion, LCE3E is a protein that is expressed in a variety of tissues throughout the body and is involved in various cellular processes. Its ability to regulate cell signaling and play a role as a biomarker for diseases has renewed interest in its potential as a drug target or therapeutic agent. Further research is needed to fully understand the role of LCE3E in various cellular processes and its potential as a therapeutic agent.

Protein Name: Late Cornified Envelope 3E

Functions: Precursors of the cornified envelope of the stratum corneum

The "LCE3E Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE3E comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets